Abstract
Whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is a diagnostic modality that can noninvasively survey the entire body and sensitively detect various cancers. In this study, we examined the potential application of whole-body PET for cancer screening in asymptomatic individuals. PET was performed in conjunction with conventional examinations including physical examination, laboratory study, ultrasonography and chest computed tomography. Between September 1994 and March 1999, 3165 asymptomatic individuals participated in 5575 screening sessions (2017 men and 1148 women; mean ± SD age, 52.2 ± 10.4 years). Follow-up periods were no less than 10 months. PET results were compared with the screening outcomes. Within 1 year after screening, malignant tumours were discovered in 67 of the 3165 participants (2.1%). PET findings were true-positive in 36 of the 67 cancers (54%). Most of the 36 patients underwent potentially curative surgery; thus a wide variety of cancers were detected by PET at potentially curable stages. However, PET findings were false-negative in 31 of the 67 patients (46%). 14 of these 31 (45%) were of urological origin. FDG PET imaging has the potential to detect a wide variety of cancers at potentially curable stages. However, PET imaging is not suited to screening test of general population because PET examination involves substantial cost. © 2000 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G, Al-Kaisi N and Miraldi F (1991) Noninvasive grading of muscloskeletal tumors using PET. J Nucl Med 32: 1508–1512
Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST and Bading JR (1996) PET and [18F]-FDG in oncology: a clinical update. Nucl Med Biol 23: 717–735
Delbeke D (1999) Oncological application of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 40: 591–603
Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA and von Schulthless GK (1996) Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 37: 441–446
Guerrero TM, Hoffman EJ, Dahlbom M, Cutler PD, Hawkins RA and Phelps ME (1990) Characterization of a whole body imaging technique for PET. IEEE Trans Nucl Sci, 676–680
Hall EJ (1994) Radiobiology for the Radiologist. Lippincott: Philadelphia
Hardcastle JD, Chamberlain JO, Robinson MHE, Moss SM, Amar SS, Balfour TW, James PD and Mangham CM (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472–1477
Henschke CI, McCauley DI, Yankelevits DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK and Smith JP (1999) Early lung cancer action project: overall design and findings from baseline screening. Lancet 354: 99–105
Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, Honda T, Inokuma T, Katsushima S, Ohshio G, Imamura M and Konishi J (1998) FDG uptake, glut-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 39: 1727–1735
Hulka BS (1988) Cancer screening: degree of proof and practical application. Cancer 62: 1776–1780
Jones SC, Alavi A, Christman D, Montanez I, Wolf AP and Reivich M (1982) The radiation dosimetry of 2-[F-18] fluoro-2-deoxy-D- glucose in man. J Nucl Med 23: 613–617
Kramer BS, Gohagan J and Prorok PC (1994) NIH consensus 1994: screening. Gyne Oncol 55: S20–21
Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Naruke T, Suemasu K and Moriyama N (1996) Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 201: 798–802
Lassen U, Daugaard G, Eigtved A, Damgaard K and Friberg L (1999) 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 35: 1076–1082
Mejia AA, Nakamura T, Itoh M, Hatazawa J, Matsumoto M and Watanuki S (1991) Estimation of absorbed dose in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J Nucl Med 32: 699–706
Miraldi F, Vesselle H, Faulhaber PF, Adler L and Leisure GP (1998) Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 23: 3–7
Nakata B, Chung YS, Nishimura S, Nishihara T, Sakurai Y, Sawada T, Okamura T, Kawabe J, Ochi H and Sowa M (1997) 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 79: 695–699
Nishizawa K, Maruyama R, Takayama M, Iwai K and Furuya Y (1995) Estimation of effective dose from CT examination. Nippon Acta Radiologica 55: 763–768
Okada J, Oonishi H, Yoshikawa K, Itami J, Uno K, Imaseki K and Arimizu N (1994) FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 8: 187–191
Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, Shishikura T, Imazeki K and Nakajima N (1998) Predicting the prognosis of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro [18F]-D-glucose. Cancer 82: 2227–2234
Price P and Jones T (1995) Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy. Eur J Cancer 31A: 1924–1927
Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T and Foidart-Willems J (1996) Oncological application of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23: 1641–1674
Robert G and Milne R (1999) A Delphi study to establish national cost-effectiveness research priorities for positron emission tomography. Eur J Radiol 30: 54–60
Sobin LH, Wittekind Ch (eds) (1997) UICC TNM Classification of Malignant Tumours. 5th ed. Wiley-Liss: New York
Taubes G (1997) The breast-screening brawl. Science 275: 1056–1059
Yasuda S and Shohtsu A (1997) Cancer screening with whole-body 18F-fluorodeoxyglucose positron-emission tomography (letter). Lancet 350: 1819
Yasuda S, Shohtsu A, Ide M, Takagi S, Takahashi W, Suzuki Y and Horiuchi M (1998) Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology 207: 775–778
Yasuda S, Shohtsu A, Ide M, Takagi S, Kijima H and Horiuchi M (1998) Elevated F-18 FDG uptake in plasmacyte-rich chronic maxillary sinusitis. Clin Nucl Med 23: 116–118
Yasuda S, Kubota M, Tajima T, Tajima T, Umemura S, Fujii H, Takahashi W, Ide M and Shohtsu A (1999) A small breast cancer detected by PET. Jpn J Clin Oncol 29: 387–389
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Yasuda, S., Ide, M., Fujii, H. et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 83, 1607–1611 (2000). https://doi.org/10.1054/bjoc.2000.1496
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1496
Keywords
This article is cited by
-
[18F]FDG PET/MRI combined with chest HRCT in early cancer detection: a retrospective study of 3020 asymptomatic subjects
European Journal of Nuclear Medicine and Molecular Imaging (2023)
-
Unintentional weight loss: what radiologists need to know and what clinicians want to know
Abdominal Radiology (2021)
-
Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening
Scientific Reports (2020)
-
Ten-year prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population
Annals of Nuclear Medicine (2020)
-
The value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in asymptomatic examinees with unexplained elevated blood carcinoembryonic antigen levels
European Journal of Nuclear Medicine and Molecular Imaging (2016)